Literature DB >> 23358745

[Pain management in palliative care. Current aspects of medicinal therapy].

H Cuhls1, L Radbruch, A Brunsch-Radbruch, G Schmidt-Wolf, R Rolke.   

Abstract

Palliative care patients do not only suffer from cancer pain but also from painful muscle spasticity due to multiple sclerosis, amyotrophic lateral sclerosis, after stroke or due to dementia if damage of the pyramidal motor system is present. Centrally active muscle relaxants can be helpful also when used as coanalgesics for cancer pain. In addition to opioids other coanalgesics, such as tricyclic antidepressants or serotonin/noradrenalin reuptake inhibitors as well as anticonvulsants (sodium channel and calcium channel blockers) can be helpful if neuropathic cancer pain is present. Idiopathic Parkinsonism or multiple system atrophy leads more to a painful rigor and pain control should be supported here by optimal adjustment of L-DOPA or DOPA agonist therapy. However, pain treatment should always address the psychological, social and spiritual demands of the patient.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23358745     DOI: 10.1007/s00108-012-3230-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  15 in total

1.  [Cancer pain in palliative medicine].

Authors:  R Laufenberg-Feldmann; R Schwab; R Rolke; M Weber
Journal:  Internist (Berl)       Date:  2012-02       Impact factor: 0.743

Review 2.  Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC.

Authors:  Augusto Caraceni; Geoffrey Hanks; Stein Kaasa; Michael I Bennett; Cinzia Brunelli; Nathan Cherny; Ola Dale; Franco De Conno; Marie Fallon; Magdi Hanna; Dagny Faksvåg Haugen; Gitte Juhl; Samuel King; Pål Klepstad; Eivor A Laugsand; Marco Maltoni; Sebastiano Mercadante; Maria Nabal; Alessandra Pigni; Lukas Radbruch; Colette Reid; Per Sjogren; Patrick C Stone; Davide Tassinari; Giovambattista Zeppetella
Journal:  Lancet Oncol       Date:  2012-02       Impact factor: 41.316

Review 3.  Opioids in renal failure and dialysis patients.

Authors:  Mervyn Dean
Journal:  J Pain Symptom Manage       Date:  2004-11       Impact factor: 3.612

4.  Long-term treatment of cancer pain with transdermal fentanyl.

Authors:  B Donner; M Zenz; M Strumpf; M Raber
Journal:  J Pain Symptom Manage       Date:  1998-03       Impact factor: 3.612

Review 5.  Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors.

Authors:  Elana M Nelson; Ann M Philbrick
Journal:  Ann Pharmacother       Date:  2012-12-04       Impact factor: 3.154

Review 6.  Buprenorphine in the treatment of opioid dependence.

Authors:  Eugen Davids; Markus Gastpar
Journal:  Eur Neuropsychopharmacol       Date:  2004-05       Impact factor: 4.600

Review 7.  Methadone.

Authors:  Shalini Chhabra; Janet Bull
Journal:  Am J Hosp Palliat Care       Date:  2008 Apr-May       Impact factor: 2.500

8.  Transdermal fentanyl for cancer pain. Repeated dose pharmacokinetics.

Authors:  R K Portenoy; M A Southam; S K Gupta; J Lapin; M Layman; C E Inturrisi; K M Foley
Journal:  Anesthesiology       Date:  1993-01       Impact factor: 7.892

9.  [Therapy with opioids in liver or renal failure].

Authors:  I Tegeder; G Geisslinger; J Lötsch
Journal:  Schmerz       Date:  1999-06-11       Impact factor: 1.107

10.  Transdermal buprenorphine in the management of persistent pain - safety aspects.

Authors:  Rudolf Likar
Journal:  Ther Clin Risk Manag       Date:  2006-03       Impact factor: 2.423

View more
  3 in total

Review 1.  [Update palliative pain therapy].

Authors:  R Rolke; S Rolke; S Hiddemann; M Mücke; H Cuhls; L Radbruch; F Elsner; V Peuckmann-Post
Journal:  Internist (Berl)       Date:  2016-10       Impact factor: 0.743

Review 2.  [Pain therapy in cancer and palliative medicine].

Authors:  R Rolke; L Radbruch
Journal:  Schmerz       Date:  2015-10       Impact factor: 1.107

3.  Matrix stimulation in cancer pain: Methodology, safety and effectiveness.

Authors:  M Mücke; M Tils; R Conrad; D Kravchenko; H Cuhls; L Radbruch; M Marinova; V Peuckmann-Post; R Rolke
Journal:  Eur J Pain       Date:  2017-08-14       Impact factor: 3.931

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.